دورية أكاديمية

[Cooccurrence of classic Hodgkin lymphoma and multiple myeloma].

التفاصيل البيبلوغرافية
العنوان: [Cooccurrence of classic Hodgkin lymphoma and multiple myeloma].
المؤلفون: Andoh S; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Yokoyama K; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Uchida S; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Makiyama J; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Kawamata T; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Yasui H; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Ota Y; Department of Pathology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Imai Y; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Tojo A; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo.
المصدر: [Rinsho ketsueki] The Japanese journal of clinical hematology [Rinsho Ketsueki] 2021; Vol. 62 (1), pp. 14-19.
نوع المنشور: Case Reports; Journal Article
اللغة: Japanese
بيانات الدورية: Publisher: Japan Society Of Clinical Hematology Country of Publication: Japan NLM ID: 2984782R Publication Model: Print Cited Medium: Print ISSN: 0485-1439 (Print) Linking ISSN: 04851439 NLM ISO Abbreviation: Rinsho Ketsueki Subsets: MEDLINE
أسماء مطبوعة: Publication: Tokyo : Japan Society Of Clinical Hematology
Original Publication: Tokyo, Rinsho Ketsueki Kondankai.
مواضيع طبية MeSH: Hodgkin Disease*/complications , Hodgkin Disease*/diagnosis , Hodgkin Disease*/therapy , Multiple Myeloma*/complications , Multiple Myeloma*/drug therapy , Multiple Myeloma*/therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Middle Aged ; Transplantation, Autologous
مستخلص: Although classic Hodgkin's lymphoma (CHL) sometimes develops after treatment for multiple myeloma (MM), simultaneous diagnosis of both malignancies is extremely rare without previous treatment history. Here we describe a case of a 54-year-old female who complained of left cervical lymphadenopathy. Biopsy specimen from the left cervical lymph node revealed mixed-cellularity CHL. Bone marrow aspirate comprised 10.3% plasma cells. She was diagnosed with MM due to involved: uninvolved serum free light chain ratio of >100. She achieved complete response for CHL after 4 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy along with 30 Gy of involved-field radiotherapy. Three years later, bortezomib, lenalidomide, and dexamethasone (VRd-lite) therapy was initiated for MM. Severe neutropenia during her 1st cycle prompted a dosage reduction of lenalidomide and bortezomib. Partial response was achieved after 4 cycles of VRd-lite followed by high-dose melphalan/autologous stem cell transplantation. No severe adverse events were recorded. This was followed by 4 cycles of carfilzomib, lenalidomide, and dexamethasone therapy, which resulted in complete remission. As the number of elderly people increases, multiple myeloma patients with previous history of other malignancies would increase. Our case has shown that VRd-lite therapy may be suitable for those patients.
فهرسة مساهمة: Keywords: Autologous stem cell transplantation; Classic Hodgkin’s lymphoma; Multiple myeloma; VRd-lite
المشرفين على المادة: 69G8BD63PP (Bortezomib)
7S5I7G3JQL (Dexamethasone)
تواريخ الأحداث: Date Created: 20210208 Date Completed: 20210211 Latest Revision: 20210211
رمز التحديث: 20240628
DOI: 10.11406/rinketsu.62.14
PMID: 33551419
قاعدة البيانات: MEDLINE
الوصف
تدمد:0485-1439
DOI:10.11406/rinketsu.62.14